Sunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights
Sunesis Pharmaceuticals (Nasdaq: SNSS) will host a conference call on August 11, 2020, at 4:30 p.m. ET to discuss its corporate updates and second-quarter financial results for the period ending June 30, 2020. Interested parties can participate by calling (844) 296-7720 for U.S. and Canada or (574) 990-1148 for international access with the passcode 3484194. The live audio webcast and archived recording will be available on the company's website.
- Sunesis is focusing on advancing its novel kinase inhibitor pipeline.
- SNS-510 is in IND-enabling studies, and vecabrutinib is completing a Phase 1b trial.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2020.
The call can be accessed by dialing (844) 296-7720 (U.S. and Canada) or (574) 990-1148 (International) and entering passcode 3484194.
To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com/events-and-presentations/upcoming-events. The webcast will be recorded and available for replay on the company's website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including first-in-class PDK1 inhibitor SNS-510 and its oral non-covalent BTK inhibitor vecabrutinib. SNS-510 is in IND-enabling studies and vecabrutinib is completing a Phase 1b trial in patients with advanced B cell malignancies.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: | ||
| Maeve Conneighton | Par Hyare | |
| Argot Partners | Sunesis Pharmaceuticals Inc. | |
| 212-600-1902 | 650-266- 3784 | |
FAQ
When will Sunesis Pharmaceuticals announce its second-quarter results?
How can I listen to the Sunesis Pharmaceuticals conference call?
What is the focus of Sunesis Pharmaceuticals?
